Aurinia Pharmaceuticals to Present at the 2015 UBS Global Health Care Conference
VICTORIA, British Columbia-- Aurinia Pharmaceuticals Inc., (NASDAQ: AUPH / TSX: AUP) today announced that its Chief Executive Officer, Stephen W. Zaruby, will present a corporate overview of the company at the 2015 UBS Global Health Care Conference, taking place May 18th – 20th, 2015 in New York at the Sheraton New York Times Square Hotel.
Aurinia Presentation Details
Date: Wednesday, May 20th, 2015
Time: 11:30 a.m. Eastern
Location: New York Sheraton Time Square Hotel – Riverside Room
Aurinia is a clinical stage pharmaceutical company focused on the global nephrology market. It is currently enrolling patients in its Phase 2b clinical trial to evaluate the efficacy of its drug, voclosporin, as a treatment for lupus nephritis (“LN”). LN is an inflammation of the kidneys, that if inadequately treated can lead to end-stage renal disease, making LN a serious and potentially life-threatening condition.
Voclosporin is a novel and potentially best in class calcineurin inhibitor (“CNI”) with extensive clinical data in over 2,000 patients in other indications. Voclosporin is made by a modification of a single amino acid of the cyclosporine molecule (a CNI approved for use in transplant patients since 1983). This modification results in a more predictable pharmacokinetic and pharmacodynamic relationship, an increase in potency vs. cyclosporine, an altered metabolic profile, and potential for flat dosing.
Visit www.auriniapharma.com for more information.
Aurinia Pharmaceuticals Inc.
Stephen Zaruby, 206-755-7520
President & Chief Executive Officer
Investor & Media Contact:
Michael R. Martin, 250-708-4272
Chief Operating Officer
Source: Aurinia Pharmaceuticals Inc.
Released May 19, 2015